Cyclerion Therapeutics Stock Revenue
| CYCN Stock | USD 2.20 0.04 1.85% |
Cyclerion Therapeutics fundamentals help investors to digest information that contributes to Cyclerion Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyclerion Stock. The fundamental analysis module provides a way to measure Cyclerion Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyclerion Therapeutics stock.
| Last Reported | Projected for Next Year |
Cyclerion | Revenue |
Cyclerion Therapeutics Company Revenue Analysis
Cyclerion Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Cyclerion
Projected quarterly revenue analysis of Cyclerion Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Cyclerion Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Cyclerion Therapeutics' stock price.
Cyclerion Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Cyclerion Therapeutics is extremely important. It helps to project a fair market value of Cyclerion Stock properly, considering its historical fundamentals such as Revenue. Since Cyclerion Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cyclerion Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cyclerion Therapeutics' interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Cyclerion Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Cyclerion Therapeutics reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Cyclerion Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclerion Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclerion Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclerion Therapeutics by comparing valuation metrics of similar companies.Cyclerion Therapeutics is currently under evaluation in revenue category among its peers.
Cyclerion Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cyclerion Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cyclerion Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Cyclerion Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Cyclerion Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cyclerion Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cyclerion Therapeutics' value.| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 K | Group One Trading, Lp | 2024-06-30 | 540 | Royal Bank Of Canada | 2024-06-30 | 416 | Activest Wealth Management | 2024-06-30 | 100.0 | Bank Of America Corp | 2024-06-30 | 16.0 | Northwestern Mutual Wealth Management Co | 2024-06-30 | 1.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Farmers National Bank | 2024-06-30 | 0.0 | Pnc Financial Services Group Inc | 2024-09-30 | 0.0 | Slate Path Capital Lp | 2024-09-30 | 357.9 K | Mfn Partners Management, Lp | 2024-06-30 | 169.5 K |
Cyclerion Fundamentals
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | 3.09 M | ||||
| Shares Outstanding | 2.71 M | ||||
| Shares Owned By Insiders | 21.90 % | ||||
| Shares Owned By Institutions | 40.41 % | ||||
| Number Of Shares Shorted | 5.5 K | ||||
| Price To Earning | (0.59) X | ||||
| Price To Book | 0.73 X | ||||
| Price To Sales | 28.31 X | ||||
| Gross Profit | (29.75 M) | ||||
| EBITDA | (12.59 M) | ||||
| Net Income | (5.26 M) | ||||
| Cash And Equivalents | 30.32 M | ||||
| Cash Per Share | 0.70 X | ||||
| Total Debt | 2.09 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 3.21 X | ||||
| Book Value Per Share | 4.56 X | ||||
| Cash Flow From Operations | (21.25 M) | ||||
| Short Ratio | 0.78 X | ||||
| Earnings Per Share | (2.08) X | ||||
| Target Price | 4.0 | ||||
| Beta | 1.92 | ||||
| Market Capitalization | 5.96 M | ||||
| Total Asset | 13.37 M | ||||
| Retained Earnings | (264.42 M) | ||||
| Working Capital | 5.94 M | ||||
| Current Asset | 109.19 M | ||||
| Current Liabilities | 18.4 M | ||||
| Net Asset | 13.37 M |
About Cyclerion Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyclerion Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclerion Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclerion Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cyclerion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclerion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclerion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Cyclerion Stock
| 0.77 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.73 | VTRS | Viatris | PairCorr |
| 0.68 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.66 | WAT | Waters | PairCorr |
| 0.51 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Cyclerion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclerion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclerion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclerion Therapeutics to buy it.
The correlation of Cyclerion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclerion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclerion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclerion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Cyclerion Therapeutics Piotroski F Score and Cyclerion Therapeutics Altman Z Score analysis. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.47) | Return On Equity (1.50) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.